Cognition Therapeutics, Inc. published results of a proteomics analysis from its Phase 2 'SEQUEL' COG0202 Study of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease. The findings were published in the peer-reviewed journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.
The SEQUEL study, which investigated zervimesine's effect on synaptic function using quantitative electroencephalography (qEEG), showed consistent trends of improvement across prespecified EEG parameters. Zervimesine treatment reduced slower 'theta' waves and improved global alpha AEC-c, suggesting normalization of neuron and synapse function and enhanced brain connectivity.
Analysis identified that proteins significantly altered by zervimesine treatment were associated with vesicle formation, exocytosis, and endosomal trafficking, which are crucial cellular functions for neuron health. In vitro studies further demonstrated zervimesine's ability to preserve neuron viability against oxidative stress, supporting its neuroprotective mechanism.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.